A Randomized, Parallel-Group, Double-Blind, Multicenter, Dose Equivalence Study of the Safety and Efficacy of Oral Lubiprostone in Subjects with Chronic Idiopathic Constipation

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223387

Enrollment

134

Registered

2016-11-21

Start date

2016-11-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Idiopathic Constipation

Interventions

investigational material(s) Generic name etc : Lubiprostone INN of investigational material : Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration for Inv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subject has history of constipation, on average, less than 3 spontaneous bowel movements per week for at least 6 months before the start of screening and during the baseline period.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Change from baseline in the frequency of spontaneous bowel movements at week 1	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026